文献速递肝病消化道肿瘤与早癌

精准治疗先驱:肝细胞癌免疫治疗的演变

Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2025-10-02

肝细胞癌(HCC)是癌症相关发病和死亡的主要原因,全身治疗是其临床管理的核心支柱,近年来免疫治疗的出现使其发生了转变。目前免疫治疗已确立的靶点包括PD-1、PD-L1、CTLA-4和VEGF,PD-1/PD-L1联合VEGF或CTLA-4的抗体组合已获批并成为一线标准治疗。免疫治疗目前仍局限于晚期HCC,但正在早期阶段进行评估;分子生物标志物和分类已开发用于指导治疗选择,但尚未在常规临床实践中采用。本文综述了HCC免疫治疗的演变,有望提高治疗精准度,从而最大化患者获益并同时降低伤害风险。

要点

  • PD-1/PD-L1联合VEGF或CTLA-4的抗体组合已获批为晚期HCC一线标准治疗。
  • 免疫治疗在HCC中目前仍限于晚期,但正在向早期阶段拓展评估。
  • 分子生物标志物尚未常规用于指导HCC免疫治疗选择。

核心结论

  • HCC免疫治疗已从晚期向早期拓展,新型靶点药物处于不同临床开发阶段,精准化有望最大化获益并降低风险。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 当前免疫治疗确立的靶点为PD-1、PD-L1、CTLA-4和VEGF。
  • PD-1/PD-L1联合VEGF及PD-1/PD-L1联合CTLA-4的抗体组合已获批并成为一线标准治疗。
  • 免疫治疗目前仍局限于晚期HCC,但正在早期阶段进行评估。
  • 分子生物标志物和分类已开发用于指导治疗选择,但尚未在常规临床实践中采用。
  • 多个新型免疫治疗靶点已被识别,相应治疗处于早期及晚期临床开发阶段。

关键数值与推荐

  • PD-1/PD-L1联合VEGF及PD-1/PD-L1联合CTLA-4的抗体组合已获批为一线标准治疗。

临床怎么用

  • 晚期HCC一线可选用PD-1/PD-L1联合VEGF或联合CTLA-4的已获批方案。
  • 分子生物标志物尚未常规用于指导HCC免疫治疗选择。
  • 关注早期HCC免疫治疗评估及新型靶点药物的临床开发进展。

局限性

  • 摘要未报告综述的检索范围及具体研究方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality. Systemic treatment is a central pillar for the clinical management of HCC, which has been transformed by the arrival of immunotherapy in recent years. The established targets of today's immunotherapeutic options are PD-1, PD-L1, CTLA-4, and VEGF. Combinations of antibodies inhibiting PD-1/PD-L1 + VEGF and PD-1/PD-L1 + CTLA-4, respectively, have received approval and represent the current standard-of-care in the first-line setting. Immunotherapy for HCC has so far been confined to the advanced stage, but is currently being evaluated in earlier stages, too. Molecular biomarkers and classifications have been developed to guide treatment selection, but have not yet been adopted in routine clinical practice. In addition, several novel immunotherapeutic targets have been identified, and treatments exploiting those targets are currently at early as well as late stages of clinical development. Herein, we review this evolution of immunotherapy for HCC, which holds the potential for increasing therapeutic precision and thus for maximizing the benefit of patients while simultaneously reducing their risk of harm.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Foerster F, Wiesmann L, Bark P, et al. Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma. Hepatology. 2025. PMID: 41037746. doi:10.1097/HEP.0000000000001554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。